What Is the Strongest ED Medication?

How PDE5 Inhibitors Work

All four approved oral ED drugs block phosphodiesterase type 5, the enzyme that breaks down cyclic GMP in penile smooth muscle. More cyclic GMP means prolonged relaxation of the cavernous arteries, greater inflow, and a firmer erection. Sexual stimulation must still trigger nitric oxide release from endothelial cells for this cascade to begin. A PDE5 inhibitor is not an aphrodisiac; without arousal, no erection follows.

The four agents differ mostly in potency at the receptor level, half-life, selectivity for PDE5 versus related enzymes, and the extent to which food slows absorption. Tadalafil, for example, inhibits both PDE5 and PDE11, the latter being expressed in testicular tissue, though clinical consequences of PDE11 inhibition remain under study. Vardenafil shows the highest PDE5 binding affinity in vitro of the older three agents, though in-vitro affinity does not always translate linearly into clinical outcomes. [1]

Understanding receptor pharmacology matters because it explains why a man who does not respond to sildenafil 100 mg might respond to tadalafil 20 mg or vardenafil 20 mg, and vice versa. Switching agents before concluding treatment failure is a standard step in the 2018 AUA Erectile Dysfunction Guideline. [2]

Sildenafil (Viagra): The Reference Standard

Sildenafil was the first oral PDE5 inhibitor approved by the FDA in March 1998, and it remains the most-prescribed ED drug globally. Standard doses are 25 mg, 50 mg, and 100 mg taken 30 to 60 minutes before sexual activity.

Onset begins as early as 30 minutes, though peak plasma concentration occurs at roughly 60 minutes in fasted men. A high-fat meal can extend time to peak by about one hour and reduce maximum concentration by 29 percent, a clinically meaningful delay for some patients. Duration of effect is 4 to 6 hours, though detectable plasma levels persist somewhat longer.

In the key phase III trial that supported FDA approval, sildenafil improved erections sufficient for intercourse in approximately 70 percent of men with ED of mixed etiology versus 22 percent on placebo. [3] The drug's half-life is 3 to 5 hours. At 100 mg, the maximum approved dose, response rates in men with severe ED (those with diabetes or post-prostatectomy) are lower, ranging from 43 to 59 percent.

Sildenafil is available as a generic at under $1 per tablet through most major pharmacy chains, making cost a real clinical factor when choosing between agents.

Can you take sildenafil every day? The FDA label approves sildenafil only for as-needed use, not daily continuous dosing. Some published research has examined daily low-dose sildenafil (25 to 50 mg) for penile rehabilitation after radical prostatectomy, but no daily formulation carries an FDA indication. If you want a daily pill, tadalafil 2.5 to 5 mg is the only FDA-approved option in that category.

Tadalafil (Cialis): Longest Duration, Only Daily Option

Tadalafil's half-life of approximately 17.5 hours is the longest of any approved PDE5 inhibitor. That extended half-life produces a clinical window of up to 36 hours, which is why the drug earned the nickname "the weekend pill."

Approved doses for as-needed use are 10 mg and 20 mg. The FDA also approved 2.5 mg and 5 mg daily-dose formulations in 2008, with the 5 mg daily dose later receiving separate approval for benign prostatic hyperplasia (BPH). Onset for on-demand dosing is typically 30 minutes, with most men reaching best effect at around 2 hours. Unlike sildenafil and vardenafil, tadalafil absorption is not meaningfully affected by food. [4]

In the key phase III trial for on-demand tadalafil, tadalafil 20 mg improved the ability to achieve vaginal penetration in 75 percent of attempts versus 32 percent with placebo. [5] The daily 5 mg dose reaches steady state in about 5 days of consecutive administration, after which spontaneous erections become more predictable without timing sex around a pill.

How long does Cialis last compared to Viagra? Tadalafil's 36-hour window is roughly six to nine times longer than sildenafil's 4 to 6 hours. For men who find timing pressure stressful, that difference has practical quality-of-life implications.

Tadalafil also inhibits PDE11, which has raised questions about effects on spermatogenesis and muscle pain. Myalgia and back pain affect roughly 6 percent of tadalafil users, a side effect profile distinct from the visual disturbances more common with sildenafil (caused by PDE6 inhibition in retinal tissue). [6]

Vardenafil (Levitra, Staxyn): Highest In-Vitro PDE5 Binding Affinity

Vardenafil binds PDE5 with roughly 10-fold greater in-vitro affinity than sildenafil. Its half-life is 4 to 5 hours. The approved dose range is 5 to 20 mg, taken 25 to 60 minutes before sex. An orally disintegrating tablet formulation (Staxyn 10 mg) dissolves under the tongue and may reach peak plasma levels slightly faster than the standard film-coated tablet.

In a randomized placebo-controlled trial, vardenafil 20 mg resulted in successful intercourse in approximately 80 percent of attempts versus 52 percent with placebo in men with mild to moderate ED. [7] That 80 percent figure is frequently cited in discussions about which agent has the best clinical response rate, though direct head-to-head trials show modest differences between agents, and patient-level factors matter more than drug choice in most cases.

Vardenafil carries one specific precaution absent from the other three agents: QTc prolongation at supratherapeutic doses. Men with congenital long QT syndrome or those taking Class IA or Class III antiarrhythmics should not use vardenafil. This interaction is documented in the FDA prescribing information for vardenafil. [8]

High-fat meals reduce peak plasma levels of vardenafil by about 20 percent, a smaller effect than sildenafil's 29 percent reduction. Generic vardenafil is available in the US but remains less widely stocked than generic sildenafil.

Avanafil (Stendra): Fastest Onset

Avanafil received FDA approval in April 2012 and is the newest of the four agents. Its primary clinical advantage is speed. At the 200 mg dose, some men experience effect onset as early as 15 minutes. The half-life is approximately 5 hours, giving a 6-hour duration of action.

Approved doses are 50 mg, 100 mg, and 200 mg. Avanafil is also the most PDE5-selective of the four agents, meaning it inhibits PDE6 and PDE11 substantially less than sildenafil or tadalafil. That selectivity may explain the lower reported rate of visual side effects (blue-tinge, blurred vision) seen with sildenafil.

In the key phase III trial for avanafil 200 mg, the mean per-patient success rate for sexual intercourse was 59 percent versus 28 percent on placebo, with a statistically significant improvement from baseline on the International Index of Erectile Function (IIEF). [9] Avanafil is not yet available in a generic formulation in the US, making it the most expensive option, typically $30 to $60 per tablet without insurance.

Food has minimal effect on avanafil absorption. For men who want spontaneity closer to sildenafil's familiarity but with a faster window, avanafil is a clinically reasonable alternative.

Head-to-Head Comparisons: What the Evidence Actually Shows

Direct comparative trials are limited, but several meta-analyses have pooled response data. A 2013 network meta-analysis published in the European Journal of Clinical Pharmacology compared all four agents and found no statistically significant difference in overall efficacy between sildenafil 100 mg, tadalafil 20 mg, vardenafil 20 mg, and avanafil 200 mg on IIEF domain scores. [10] Patient preference, tolerability, and dosing flexibility drove adherence more than raw potency differences.

A 2017 Cochrane systematic review of PDE5 inhibitors for ED concluded that all approved agents are effective and generally well tolerated. [11] The review noted that men with diabetes, post-prostatectomy, or severe vascular disease have lower response rates across all agents, typically 40 to 60 percent versus 70 to 80 percent in men with psychogenic or mild vascular ED.

HealthRX Clinical Decision Framework: Matching Agent to Patient Profile

| Patient Profile | First-Line Agent | Rationale | |---|---|---| | Prefers timing flexibility | Tadalafil 20 mg on-demand | 36-hour window | | Prefers daily dosing + BPH | Tadalafil 5 mg daily | Only dual-indication agent | | Cost-sensitive | Generic sildenafil 50-100 mg | Under $1/tablet widely available | | Fastest possible onset needed | Avanafil 200 mg | 15-minute onset data | | Visual side effects with sildenafil | Avanafil or tadalafil | Lower PDE6 inhibition | | Post-prostatectomy rehabilitation | Sildenafil or tadalafil daily | Published penile rehab data | | Cardiac rhythm concerns | Sildenafil or tadalafil | Vardenafil has QTc signal |

This framework is intended as a starting-point discussion tool between patient and prescriber, not a substitute for individualized clinical evaluation.

Why Doesn't Viagra Work for Me?

Sildenafil failure is more common than many patients expect. Reported non-response rates in real-world practice range from 30 to 50 percent depending on how failure is defined. Several factors explain most cases.

Insufficient arousal. PDE5 inhibitors require sexual stimulation to generate nitric oxide. Men who take sildenafil and then wait passively often report no effect. Physical and psychological arousal must be present.

Wrong timing or food interaction. Taking sildenafil within 30 minutes of a high-fat meal significantly blunts and delays peak concentration. The label recommends taking it on an empty stomach or after a light meal. Many first-time users make this error.

Inadequate dose. Starting at 25 mg or 50 mg is appropriate for safety, but some men need the full 100 mg for adequate response. The FDA label states that a starting dose of 50 mg is recommended, with adjustment to 100 mg or 25 mg based on efficacy and tolerability. [12]

Underlying vascular disease. Severe atherosclerosis limits nitric oxide release and cavernous artery dilation regardless of PDE5 inhibition. A 2020 review in the Journal of Sexual Medicine noted that cardiovascular risk factors including hypertension, dyslipidemia, and diabetes are independent predictors of PDE5 inhibitor non-response. [13] In these patients, addressing the underlying condition improves response rates.

Low testosterone. Testosterone supports nitric oxide synthase expression. Men with hypogonadism (total testosterone <300 ng/dL) frequently experience PDE5 inhibitor failure. A randomized trial in the Journal of Urology found that adding testosterone replacement to sildenafil in hypogonadal non-responders improved IIEF scores significantly over sildenafil alone. [14]

Drug interactions. Strong CYP3A4 inhibitors such as ketoconazole and ritonavir substantially increase sildenafil plasma levels, requiring dose reduction to 25 mg. Conversely, CYP3A4 inducers like rifampin can reduce sildenafil levels enough to cause apparent treatment failure. Providing a complete medication list to your prescriber before starting is non-negotiable.

Psychological factors. Performance anxiety creates a feedback loop that blunts erectile response even when plasma drug levels are adequate. Cognitive behavioral therapy combined with PDE5 inhibition shows better outcomes than medication alone in several small randomized trials. [15]

Dosing, Timing, and Safety Across All Four Agents

The absolute contraindication shared by all four agents is concurrent nitrate use. Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and recreational nitrates ("poppers" containing amyl nitrite or butyl nitrite) can produce severe, potentially fatal hypotension when combined with any PDE5 inhibitor. This contraindication has no minimum safe interval; the combination should never occur.

Men taking alpha-blockers for hypertension or BPH should start at lower PDE5 inhibitor doses because additive hypotension is possible. Tadalafil 5 mg daily is the only PDE5 inhibitor with a dedicated clinical trial program in men on stable alpha-blocker therapy, which partly explains its FDA approval for concurrent BPH treatment.

Common side effects across all four agents include headache (10 to 16 percent), flushing (4 to 12 percent), nasal congestion (4 to 9 percent), and dyspepsia (4 to 12 percent). These are generally dose-dependent and mild to moderate. Sudden vision loss (non-arteritic anterior ischemic optic neuropathy, NAION) and sudden hearing loss are rare but serious adverse events listed in all four labels. Men with a history of NAION in one eye should discuss risk with their ophthalmologist before using any PDE5 inhibitor.

Priapism, an erection lasting longer than 4 hours, occurs in under 0.1 percent of users but requires immediate emergency evaluation to prevent permanent tissue damage. Men with sickle cell disease, multiple myeloma, or leukemia have elevated risk.

Special Populations: Diabetes, Post-Prostatectomy, and Cardiovascular Disease

Diabetes. Diabetic men have lower PDE5 inhibitor response rates due to endothelial dysfunction, autonomic neuropathy, and lower testosterone. In a randomized trial of sildenafil in 268 men with type 2 diabetes, 56 percent reported improved erections versus 10 percent on placebo. [16] Starting at the highest tolerated dose and addressing glycemic control simultaneously improves outcomes.

Post-radical prostatectomy. Nerve-sparing technique preserves some erectile function, but bilateral nerve-sparing still leaves 50 to 60 percent of men with ED at one year. Early penile rehabilitation with daily PDE5 inhibition may preserve penile tissue oxygenation. A randomized study of 76 men found that nightly sildenafil 100 mg for 36 weeks after nerve-sparing prostatectomy improved return of spontaneous erections compared to on-demand use. [17]

Cardiovascular disease. The Princeton Consensus Panel, last updated in 2012, stratifies men into low, moderate, and high cardiac risk before prescribing PDE5 inhibitors. Men with stable, well-controlled cardiovascular disease are generally in the low-risk category and can safely use PDE5 inhibitors. The full consensus statement is available through the American Journal of Cardiology. [18] High-risk patients, including those with unstable angina or decompensated heart failure, should defer ED treatment until cardiovascular status is stabilized.

Generic vs. Brand-Name: Is There a Clinical Difference?

Generic sildenafil, tadalafil, and vardenafil have been available in the US since 2017 to 2018, and 2018 respectively. The FDA requires bioequivalence within 80 to 125 percent of the brand-name product's area under the curve and peak concentration. In practice, generics from major manufacturers perform comparably to brand-name versions in clinical use. No peer-reviewed trial has demonstrated meaningful efficacy differences between brand and generic formulations for these agents. Cost differences, however, are substantial: generic sildenafil can cost under $1 per 100 mg tablet at major pharmacies, while brand-name Viagra can exceed $60 per tablet without coverage. Avanafil remains brand-name only (Stendra) as of mid-2025.

Combining Agents or Using Higher Doses

Men sometimes ask whether taking sildenafil and tadalafil together increases effect. Combining two PDE5 inhibitors is not FDA-approved, has not been studied in adequately powered trials, and substantially increases the risk of hypotension and other adverse events. No data support this approach.

Exceeding the maximum approved doses, such as taking two 100 mg sildenafil tablets, does not proportionally increase efficacy and sharply increases side effects. Dose-response data from the key sildenafil trials show that the 100 mg dose does not produce significantly higher IIEF scores than 50 mg in most patients, though 100 mg does improve outcomes in men who are partial non-responders to 50 mg. [3] Dose escalation within the approved range, not combination therapy, is the evidence-supported step when response is inadequate.

When Oral Medications Fail: Next Steps

Men who fail two to three adequate trials of at least two different PDE5 inhibitors, taken correctly at maximum doses, are candidates for second-line therapy. Options include intraurethral alprostadil (MUSE), intracavernosal injection therapy (alprostadil alone or in combination with papaverine and phentolamine, known as "trimix"), low-intensity shockwave therapy, and, for men with clear vascular anatomy, penile prosthesis implantation.

Trimix injections have a clinical success rate above 85 percent even in men who have failed oral PDE5 inhibitors, including those with severe vascular disease or complete post-prostatectomy ED. The AUA 2018 guideline supports intracavernosal injection as a standard second-line option. [2]

Psychological evaluation is appropriate for any man at any stage of treatment, particularly those whose ED has a clear situational or relationship-specific pattern.